低分子肝素治疗重度子痫前期合并胎儿生长受限患者的疗效分析  

Clinical Analysis on the Effects of Low Molecular Weight Heparin in Severe Pre-eclampsia with Intrauterine Growth Restriction

作　　者：傅菁[1] 许银燕[1] 王俐[1] 陈燕妮[1] 王琪[2] 丁虹娟[2] 

机构地区：[1]南京市妇幼保健院药学部,南京210004 [2]南京市妇幼保健院产科,南京210004

出　　处：《药学与临床研究》2015年第4期388-390,共3页Pharmaceutical and Clinical Research

基　　金：南京医科大学科技发展基金面上项目(2013NJMU120)

摘　　要：目的:探讨低分子肝素治疗重度子痫前期合并胎儿生长受限患者的临床有效性与安全性。方法:收集60例该病患者,等分为两组,对照组给予常规治疗,实验组在常规治疗同时加用低分子肝素治疗。观察患者肾功能、胎儿脐血流指标及对母婴结局的影响。结果:治疗后实验组尿酸水平、白蛋白水平、24 h尿蛋白、RI值、S/D值、胎儿平均体重与常规治疗组相比显著改善(P<0.05)。实验组分娩时妊娠天数延长1周左右(P<0.05)。结论:低分子肝素治疗该病患者安全、有效。Objective: It is aimed to investigate the feasibility of expectant treatment which used low molecular weight heparin (LMWH) in patients of severe pre-eclampsia combined with intrauterine growth restriction and analyzed the influence on maternal and fetal outcomes. Methods: Sixty patients with severe pre-eclampsia with intrauterine growth restriction were divided into two groups randomly; the control group (30 cases) received the normal therapy; while the observation group (30 cases) received an additional therapy of LMWH. The influence on the renal function, the umbilical arterial blood flow parameters, and the maternal and fetal outcomes between the two groups were compared. Results: Compared with the control group, the levels of uric acid, albumin and 24 hour urine protein in the observation group were significantly improved (P<0.05). Umbilical artery blood flow parameters as indicators for determining the fetal status, the S/D and RI in the observation group were significantly lower than those in the control group (P<0.05). The birth weight of neonate between the two groups showed significant difference (P<0.05). The length of expectant treatment in the control group was significantly shorter than in the observation group (P<0.05). Conclusion: The application of LMWP in severe pre-eclampsia with intrauterine growth restriction is effective and safe.

关 键 词：低分子肝素 重度子痫前期 胎儿生长受限 肾功能 脐血流 妊娠结局 

分 类 号：R969.4[医药卫生—药理学]